Statement: Zantac (ranitidine) litigation

GSK plc (LSE/NYSE: GSK) today confirmed it has reached a confidential settlement with Boyd/Steenvoord, resolving the case filed in California state court. The case, which was set to begin trial on 2 April 2024, will be dismissed. The settlement reflects the Company’s desire to avoid the distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q4 Results for 2023.